Skip to content

Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.

Optimal Timing of Endoscopic Intervention After Extracorporeal Shock-Wave Lithotripsy in the Treatment of Chronic Pancreatitis With Pancreatic Stones.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05270434
Acronym
TEST
Enrollment
220
Registered
2022-03-08
Start date
2025-03-12
Completion date
2025-10-20
Last updated
2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis, Chronic

Keywords

Extracorporeal Shock Wave Lithotripsy(ESWL), Chronic pancreatitis, Endoscopic Retrograde Cholangiopancreatography(ERCP), Pancreatic stones

Brief summary

This study aims to determine the optimal timing of endoscopic intervention after extracorporeal shock wave lithotripsy(ESWL) of chronic pancreatitis with pancreatic stones.

Detailed description

Chronic pancreatitis(CP)is a chronic progressive fibro-inflammatory disease of the pancreas induced by a wide range of factors including genetic and environmental elements, with recurrent abdominal pain and pancreatic secretion insufficiency as its major clinical signs. Chronic pancreatitis is not only a tough disease of the gastrointestinal system but also a worldwide medical problem. At present, the MESS (medicine-extracorporeal shock wave lithotripsy-endoscopic retrograde cholangiopancreatography-surgery)formed by changhai hospital in CP diagnosis and treatment is gradually becoming mature, and the clinical effect of this system is obvious. However, there are still some difficulties and knowledge gaps in the clinical treatment of CP. Currently, it is recommended by both domestic and foreign guidelines that ERCP combined with ESWL as the first-line treatment pattern for patients with chronic pancreatitis associate pain. It has previously been observed that ERCP performed less than 2 days after ESWL may be more likely to fail, possibly owing to ESWL-induced edema. However, there is no high-quality research to demonstrate how to choose the most optimal timing of ERCP after ESWL for patients with indications for endoscopic treatment. This prospective, randomized controlled research has therefore aimed to determine the most optimal timing of ERCP after ESWL. Patients with painful chronic pancreatitis and pancreatic stones larger than 5 mm in diameter will be randomly and equally assigned to two groups, which are divided according to the time interval between ESWL and ERCP, including the same day (\< 12 hours) subgroup and the next day ( ≥12 hours) subgroup. The cannulation success rate and stone clearance rate of the pancreatic duct will be assessed in each group to explore the most appropriate timing of ERCP, and then provide an important reference basis for the clinical treatment of chronic pancreatitis.

Interventions

PROCEDUREtime interval between ESWL and ERCP is 12h

The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.

PROCEDUREtime interval between ESWL and ERCP is greater than 12h

The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP ≥12 h.

DRUGmorphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)

Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.

Sponsors

Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. symptomatic adult patients diagnosed with chronic pancreatitis and main pancreatic duct positive stones(\>5mm in diameter) 2. no ERCP and ESWL history before the admission 3. provides informed consent

Exclusion criteria

1. suspected to have malignant tumors; 2. history of pancreatic surgery or gastrojejunostomy (Billroth II); 3. with end-stage disease; 4. with contraindications to ESWL or ERCP, such as pregnancy, abdominal aortic aneurysm, etc. 5. acute pancreatitis within 3 days 6. pancreatic ascites

Design outcomes

Primary

MeasureTime frameDescription
Successful MPD Cannulation Ratesduring ERCP proceduretechnical success rate of pancreatic cannulation

Secondary

MeasureTime frameDescription
Successful clearance of MPD stonesduring ERCP procedureDuctal clearance has been defined as complete, partial, or unsuccessful if the proportion of stones cleared was \> 90 %, 50 %-90 %, or \< 50 %, respectively.
post-ERCP complications30 daysMajor post-ERCP complications includes post-ERCP pancreatitis, bleeding, infection, and perforation, which are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment.
severity of post-ERCP complications30 daysseverity are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment.

Other

MeasureTime frameDescription
Treatment-related costs in RMB from initial enrollment to the end of the studythrough endotherapy completion, an average of 14daysThe total costs in RMB of each hospitalization
The hospitalization timethrough endotherapy completion, an average of 14daysLength of hospitalization due to ESWL /ERCP and complications

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026